Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD0901 + Liposomal irinotecan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD0901 | AZD-0901|AZD 0901 | CLDN18.2 Antibody 19 | Limited information is currently available on AZD0901, a putative antibody-drug conjugate (ADC) targeting CLDN18.2 (Jan 2024). | |
Liposomal irinotecan | Onivyde | PEP02|nal-IRI|MM-398|Irinotecan Sucrosofate | TOPO1 inhibitor 11 | Onivyde (liposomal irinotecan) comprises irinotecan encapsulated in liposomal nanoparticles, which may result in increased tumor growth inhibition (PMID: 23406728, PMID: 16540680, PMID: 29945562). Onivyde (liposomal irinotecan) in combination with chemotherapy is FDA-approved for use in patients with metastatic pancreatic adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06219941 | Phase II | AZD0901 + Irinotecan AZD0901 + Liposomal irinotecan AZD0901 + Leucovorin AZD0901 + Fluorouracil AZD0901 + Gemcitabine AZD0901 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Recruiting | USA | GBR | ESP | CAN | AUS | 8 |